查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677253

重组尿酸酶市场按产品类型、给药途径、应用和最终用户划分 - 2025 年至 2030 年全球预测

Recombinant Uricase Market by Product Type, Route Of Administration, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

重组尿酸酶市场规模预计在 2024 年达到 14.4 亿美元，在 2025 年达到 15.3 亿美元，年复合成长率为 5.94%，到 2030 年达到 20.4 亿美元。

主要市场统计数据
基准年 2024 年 14.4亿美元
预计 2025 年 15.3亿美元
预测年份 2030 20.4亿美元
复合年增长率（%） 5.94％

重组尿酸酶市场处于尖端生物技术创新和大量临床需求的交汇处。在本报告中，我们介绍了重组尿酸酶的复杂概况，并探讨了其在治疗性介入介入中的变革作用。生物製药的快速发展和基因工程的进步正在扩大重组尿酸酶的潜在应用。该市场专注于尿酸水平异常突出的情况，包括某些肾臟和代谢疾病，为性能、安全性和改善患者结果提供关键见解。此外，新兴的临床资料和正在进行的研究正在重新定义重组尿酸酶超越传统治疗方法的价值提案。本介绍分析建立了一个框架来理解酵素疗法的细微差别，同时深入探讨市场驱动因素、监管挑战和科学突破的影响。该报告旨在为行业专业人士和决策者提供服务，深入了解当前市场表现以及未来市场发展，以及在竞争日益激烈的全球医疗保健领域改善治疗结果的途径。

改变重组尿酸酶市场

过去几年中，在科学快速进步和产业模式不断发展的推动下，重组尿酸酶市场发生了动态变化。分子工程和製程优化的重大进展促使从传统酵素疗法转向新型生物製药製剂的转变。最近，聚乙二醇化技术和非聚乙二醇化製剂的改进重新定义了这些治疗酵素的耐受性和药物动力学特征。此外，监管部门的核准和监督力度的加强使得临床试验的方法更加标准化，以确保新配方的有效性和安全性。此外，数位监控系统和以患者为中心的资料收集的整合使得治疗通讯协定的调整更加精确，从而增强了市场信心。这种演变并不是孤立的现象，而是代表了全球迈向个人化医疗的一致步伐。投资者和临床研究人员越来越关注先进生物加工、产品差异化和改善医疗保健之间的相互作用。总的来说，这些发展建立了一个强大的框架，以促进新产品创新，优化供应链效率，并开创科学与商业之间更复杂的相互关係时代。预计此类转变将重塑市场策略，并在未来几年推动与竞争对手的差异化。

重组尿酸酶市场的关键细分见解

重组尿酸酶市场的详细细分描绘出一个多方面的故事，其中融合了特定产品和特定应用的策略以及地理和最终用户的考虑。按产品类型进行的评估重点是重组尿酸酶、非聚乙二醇化尿酸酶和聚乙二醇化尿酸酶生物仿製药，每种产品都表现出独特的特性和临床益处，与治疗领域的目标群体产生共鸣。给药途径增加了进一步的见解，临床结果显示肌肉注射、静脉注射和皮下注射系统之间存在差异。根据应用，市场对癌症治疗、肾臟病学、神经系统疾病和罕见遗传疾病等不同治疗领域进行了广泛的分析。该报告提供了痛风治疗的详细观点，强调了慢性痛风、高尿酸血症、难治性痛风和肿瘤崩坏症候群等子类别，说明了不断变化的临床需求。此外，基于最终用户的细分探讨了医疗保健提供者、製药商和研发组织如何利用这些创新来推动采用并优化以患者为中心的护理。医疗保健提供者部门对诊所、透析中心和医院进行了深入分析，强调了利用模式和治疗结果的差异。这种市场区隔洞察不仅凸显了影响市场动态的多因素考虑，而且还透过微调对目标群体及其个人需求的理解来实现更好的策略规划和合理的产品定位。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球痛风和高尿酸血症盛行率不断上升
      • 提高对标靶治疗和个人化医疗方法的认识
      • 不断扩大的患者群体、新的药物治疗方案和支持性法规结构
    • 限制因素
      • 重组尿酸酵素治疗高成本
    • 机会
      • 开发具有更高功效和安全性的新型尿酸酶治疗方法
      • 加强监管奖励，包括孤儿药指定，以鼓励创新
    • 任务
      • 可能的副作用和抗药性抗体的产生
  • 市场区隔分析
    • 产品类型：在需要快速管理复杂性痛风和高尿酸血症的急性照护环境中，非聚乙二醇化尿酸酶是首选。
    • 用途：对控制高尿酸水平的实用解决方案的持续需求导致了痛风治疗的广泛采用。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

6. 重组尿酸酶市场（依产品类型）

  • 重组尿酸酶的生物相似药
  • 非聚乙二醇化尿酸酶
  • 聚乙二醇化尿酸酶

7. 重组尿酸酶市场依给药途径划分

  • 肌肉注射
  • 静脉
  • 皮下

8. 重组尿酸酶市场（依应用）

  • 癌症治疗
  • 痛风治疗
    • 慢性痛风
    • 高尿酸血症
    • 难治性痛风
    • 肿瘤崩坏症候群
  • 肾臟疾病
  • 神经系统疾病
  • 罕见遗传疾病

9. 重组尿酸酶市场（依最终用户划分）

  • 医疗保健提供者
    • 诊所
    • 透析中心
    • 医院
  • 製药商
  • 研究开发研究所

10. 美洲重组尿酸酶市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区重组尿酸酶市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲重组尿酸酶市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • 3SBio Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Biosynth Ltd
  • Creative Enzymes
  • CUSABIO TECHNOLOGY LLC
  • GenScript Biotech Corporation
  • Hzymes Biotech
  • Innovent Biologics, Inc.
  • Kikkoman Corporation
  • Merck KGaA
  • OYC Americas, Inc.
  • Protalix BioTherapeutics
  • Sisco Research Laboratories Pvt. Ltd.
  • Swedish Orphan Biovitrum AB
Product Code: MRR-094390F400F7

The Recombinant Uricase Market was valued at USD 1.44 billion in 2024 and is projected to grow to USD 1.53 billion in 2025, with a CAGR of 5.94%, reaching USD 2.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.44 billion
Estimated Year [2025] USD 1.53 billion
Forecast Year [2030] USD 2.04 billion
CAGR (%) 5.94%

The recombinant uricase market stands at the confluence of cutting-edge biotechnology innovation and significant clinical demand. This report introduces the intricate landscape of recombinant uricase, exploring its transformative role in therapeutic interventions. The rapid evolution in biopharmaceuticals, paired with advances in genetic engineering, has expanded the potential for recombinant uricase applications. With a focus on conditions marked by aberrant uric acid levels, such as certain renal and metabolic disorders, this market offers crucial insights into performance, safety, and improved patient outcomes. Furthermore, emerging clinical data and ongoing research are redefining the value proposition of recombinant uricase beyond traditional treatments. This introductory analysis establishes a framework for understanding the nuances of enzymatic therapy, while taking a deep dive into market drivers, regulatory challenges, and the implications of scientific breakthroughs. The report is structured to serve industry professionals and decision-makers by demonstrating not just current market performance, but also pathways for future development and enhanced therapeutic efficacy in an increasingly competitive global health arena.

Transformative Shifts in the Recombinant Uricase Landscape

Over the past few years, the recombinant uricase market has experienced dynamic shifts propelled by rapid scientific advancement and evolving industry paradigms. Significant progress in molecular engineering and process optimization has driven the transition from conventional enzyme therapies to novel biopharmaceutical formulations. In recent times, improvements in pegylation techniques and non-pegylated formulations have redefined the tolerability and pharmacokinetic profiles of these therapeutic enzymes. Regulatory approvals and heightened scrutiny have also catalyzed a more standardized approach to clinical trials, ensuring that novel formulations are both efficacious and safe. Furthermore, integration of digital monitoring systems and patient-centric data collection has enabled more precise adjustments in therapy protocols, thereby bolstering market confidence. These evolutionary shifts are not isolated phenomena; rather, they represent a concerted global movement toward personalized medicine. Investors and clinical researchers are increasingly focusing on the interplay of advanced bioprocessing, product differentiation, and improved healthcare delivery methods. Collectively, these developments have established a robust framework that inspires new product innovation, optimizes supply chain efficiencies, and ushers in an era where science and commerce are more intricately connected. Such shifts are expected to realign market strategies and drive competitive differentiation in the coming years.

Key Segmentation Insights in the Recombinant Uricase Market

In-depth segmentation of the recombinant uricase market reveals a multifaceted narrative that integrates both product and application specific strategies alongside regional and end-user considerations. When evaluated on the basis of product type, the study zeroes in on biosimilars of recombinant uricase, non-pegylated uricase, and pegylated uricase, each displaying unique properties and clinical benefits that resonate with targeted segments in the therapeutic arena. The route of administration further refines these insights, documenting variations in clinical outcomes between intramuscular, intravenous, and subcutaneous delivery systems. In terms of application, the market is expansively analyzed across diverse therapeutic areas including cancer treatment, kidney diseases, neurological disorders, and rare genetic disorders. A closer examination of gout treatment provides a granular perspective, shedding light on chronic gout, hyperuricemia, refractory gout, and tumor lysis syndrome subcategories that indicate evolving clinical demands. Additionally, the segmentation based on end-users examines how healthcare providers, pharmaceutical manufacturers, and research and development institutes leverage these innovations to drive adoption and optimize patient-centric care. Within the healthcare provider segment, clinics, dialysis centers, and hospitals are analyzed in detail to highlight differential utilization patterns and therapeutic outcomes. These segmentation insights not only underscore the multifactorial considerations that shape market dynamics but also fine-tune the understanding of target groups and their individual needs, thereby enabling more precise strategic planning and streamlined product positioning.

Based on Product Type, market is studied across Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, and Pegylated Uricase.

Based on Route Of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Application, market is studied across Cancer Treatment, Gout Treatment, Kidney Diseases, Neurological Disorders, and Rare Genetic Disorders. The Gout Treatment is further studied across Chronic Gout, Hyperuricemia, Refractory Gout, and Tumor Lysis Syndrome.

Based on End-User, market is studied across Healthcare Providers, Pharmaceutical Manufacturers, and Research & Development Institutes. The Healthcare Providers is further studied across Clinics, Dialysis Centers, and Hospitals.

Regional Perspectives on the Recombinant Uricase Market

A comprehensive regional analysis brings to light distinct opportunities and operational challenges across key geographic territories. In the Americas, robust economic growth coupled with advanced healthcare infrastructures has led to significant demand for novel therapeutic agents, with recombinant uricase steadily gaining traction in clinical protocols. In contrast, the Europe, Middle East & Africa region presents a diverse portfolio of regulatory frameworks and financing mechanisms. Here, mature healthcare markets are leveraging established research networks and robust logistics to foster innovation and deliver tailored healthcare solutions. Meanwhile, the Asia-Pacific region has emerged as a rapidly expanding market driven by rising healthcare expenditures, expansive patient pools, and substantial governmental support for biotechnology research. Each region presents its own unique set of challenges and advantages, ranging from regulatory simplification and cross-border collaboration to competitive pricing strategies and high adoption rates in emerging economies. The intricate interplay between political stability, fiscal policies, and localized regulatory frameworks across these regions propels market growth, while the evolving consumer demand in each territory emphasizes the need for agile strategies and region-specific market entry tactics. This analysis brings forth key regional insights that are critical for stakeholders to navigate the differing market landscapes efficiently and capitalize on the inherent opportunities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Key Market Players in the Recombinant Uricase Field

The competitive landscape of the recombinant uricase market is marked by the presence of a diverse array of companies that are continuously driving industry advancements and innovation. Companies such as 3SBio Inc. and BioCryst Pharmaceuticals, Inc. have distinguished themselves through a strong track record in enzyme research and clinical trial execution. Firms like Biosynth Ltd and Creative Enzymes are recognized for their strategic investments in bioprocessing technologies, which have enhanced product scalability and quality control. The market further benefits from the contributions of organizations such as CUSABIO TECHNOLOGY LLC and GenScript Biotech Corporation, which have excelled in offering customized solutions that enhance the flexibility and precision of recombinant uricase formulations. Market leaders including Hzymes Biotech and Innovent Biologics, Inc. have ushered in groundbreaking advancements through innovative drug delivery mechanisms and improved bioconjugation processes. Additionally, prominent industry players such as Kikkoman Corporation, Merck KGaA, and OYC Americas, Inc. have operationalized extensive research networks and leveraged global supply chains to sustain their competitive edge. Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB also contribute significantly by integrating research excellence with robust manufacturing capabilities. These key companies collectively stimulate innovation, shape regulatory standards, and drive market dynamics that benefit a broader spectrum of stakeholders. Their strategic initiatives not only foster competitive differentiation but also serve as pivotal drivers in reducing time-to-market for next-generation formulations.

The report delves into recent significant developments in the Recombinant Uricase Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., BioCryst Pharmaceuticals, Inc., Biosynth Ltd, Creative Enzymes, CUSABIO TECHNOLOGY LLC, GenScript Biotech Corporation, Hzymes Biotech, Innovent Biologics, Inc., Kikkoman Corporation, Merck KGaA, OYC Americas, Inc., Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB. Actionable Recommendations for Industry Leaders in Recombinant Uricase

Industry leaders are encouraged to harness the momentum of current market dynamics by adopting targeted strategies that align with emerging technological trends and patient-centric demands. It is imperative to invest in research and development to refine existing formulations and explore innovative delivery platforms that can enhance therapeutic efficacy and patient adherence. Organizations should prioritize collaborations with clinical research institutes to validate novel hypotheses and accelerate the translation of cutting-edge discoveries into viable products. In addition, the integration of digital tools and real-time data analytics can empower decision-makers with deeper insights into market behavior and patient outcomes. Strengthening supply chain optimization and adopting agile manufacturing frameworks can further mitigate risks associated with regulatory complexities and market volatility. Simultaneously, fostering strong partnerships across the healthcare continuum-from academic research to hospital networks-ensures that insights gleaned from clinical practice are seamlessly integrated into product development processes. Strategic market segmentation and targeted marketing campaigns can significantly enhance brand recall and customer engagement among key stakeholders. Leaders are also advised to leverage regulatory incentives and seek collaborative platforms for knowledge exchange, thus positioning themselves at the forefront of industry innovation. By marrying technological advancements with strategic foresight, industry stakeholders can create a sustainable competitive advantage while addressing unmet clinical needs.

Conclusion: Synthesizing Market Analysis and Future Directions

The recombinant uricase market is experiencing remarkable growth, driven by simultaneous advancements in biotechnology and evolving clinical demands. This comprehensive analysis has highlighted the interplay of product innovations, detailed segmentation insights, and regional market dynamics, offering a panoramic view of the current and emerging trends. As the market continues to evolve, stakeholders are urged to stay ahead by embracing technological innovations and leveraging strategic partnerships that span across research, regulatory, and operational domains. The rigorous review of market segmentation-spanning product types, routes of administration, and application areas-coupled with insightful regional and corporate analyses, sets a clear path to capitalize on emerging opportunities. As this field matures, the synthesis of clinical data with innovative manufacturing processes will further refine the therapeutic landscape, ultimately improving patient outcomes. Decision-makers must navigate these shifting paradigms through a structured approach that integrates rigorous market analysis with proactive strategic investments. In summary, the confluence of research excellence, industry collaboration, and agile market responses is steering the recombinant uricase market towards a robust and sustainable future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gout and hyperuricemia worldwide
      • 5.1.1.2. Growing awareness of targeted therapies and personalized medicine approaches
      • 5.1.1.3. Expansion of patient population, novel drug formulations, and supportive regulatory frameworks
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of recombinant uricase therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel uricase therapies with improved efficacy and safety profiles
      • 5.1.3.2. Increasing regulatory incentives, including orphan drug status, encouraging innovation
    • 5.1.4. Challenges
      • 5.1.4.1. Potential for adverse reactions and the development of anti-drug antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type : High preference for non-pegylated uricase in acute care settings requiring swift management of complicated gout and hyperuricemia
    • 5.2.2. Application : Significant adoption of gout treatment due to the ongoing need for practical solutions managing elevated uric acid levels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Recombinant Uricase Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biosimilars of Recombinant Uricase
  • 6.3. Non-Pegylated Uricase
  • 6.4. Pegylated Uricase

7. Recombinant Uricase Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous
  • 7.4. Subcutaneous

8. Recombinant Uricase Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Treatment
  • 8.3. Gout Treatment
    • 8.3.1. Chronic Gout
    • 8.3.2. Hyperuricemia
    • 8.3.3. Refractory Gout
    • 8.3.4. Tumor Lysis Syndrome
  • 8.4. Kidney Diseases
  • 8.5. Neurological Disorders
  • 8.6. Rare Genetic Disorders

9. Recombinant Uricase Market, by End-User

  • 9.1. Introduction
  • 9.2. Healthcare Providers
    • 9.2.1. Clinics
    • 9.2.2. Dialysis Centers
    • 9.2.3. Hospitals
  • 9.3. Pharmaceutical Manufacturers
  • 9.4. Research & Development Institutes

10. Americas Recombinant Uricase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Uricase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Uricase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Protalix BioTherapeutics receives USD 20 million milestone to fuel pipeline expansion
    • 13.3.2. Protalix BioTherapeutics launches a phase I first-in-human trial evaluating PRX-115
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3SBio Inc.
  • 2. BioCryst Pharmaceuticals, Inc.
  • 3. Biosynth Ltd
  • 4. Creative Enzymes
  • 5. CUSABIO TECHNOLOGY LLC
  • 6. GenScript Biotech Corporation
  • 7. Hzymes Biotech
  • 8. Innovent Biologics, Inc.
  • 9. Kikkoman Corporation
  • 10. Merck KGaA
  • 11. OYC Americas, Inc.
  • 12. Protalix BioTherapeutics
  • 13. Sisco Research Laboratories Pvt. Ltd.
  • 14. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT URICASE MARKET MULTI-CURRENCY
  • FIGURE 2. RECOMBINANT URICASE MARKET MULTI-LANGUAGE
  • FIGURE 3. RECOMBINANT URICASE MARKET RESEARCH PROCESS
  • FIGURE 4. RECOMBINANT URICASE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RECOMBINANT URICASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RECOMBINANT URICASE MARKET DYNAMICS
  • TABLE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY BIOSIMILARS OF RECOMBINANT URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HYPERURICEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REFRACTORY GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY TUMOR LYSIS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RESEARCH & DEVELOPMENT INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 284. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 285. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024